Abstract: A memantine paroxetine cocrystal salt and its preparation method, pharmaceutical composition and application thereof are provided. The cocrystal salt of the invention is memantine paroxetine sulfate hydrate. Its mechanism of action is 5-HT inhibitor and NMDA receptor antagonist. It is a multi-target drug. The preliminary pharmacokinetic experiments showed that the main pharmacokinetic parameters of cocrystal salt and memantine, such as T1/2, Tmax, Cmax and AUC(0-?), were significantly different. The results also showed that cocrystal salt could improve drug absorption, blood drug concentration, bioavailability and curative effect. This provides a material basis for reducing dosage and adverse drug reactions. In addition to that the cocrystal salt of this invention can be used as a multi-target drug, it can also combine with other drugs of different action mechanisms to form compound preparations or be used in combination, so as to obtain unexpected clinical efficacy.

Abstract: A memantine paroxetine cocrystal salt and its preparation method, pharmaceutical composition and application thereof are provided. The cocrystal salt of the invention is memantine paroxetine sulfate hydrate. Its mechanism of action is 5-HT inhibitor and NMDA receptor antagonist. It is a multi-target drug. The preliminary pharmacokinetic experiments showed that the main pharmacokinetic parameters of cocrystal salt and memantine, such as T1/2, Tmax, Cmax and AUC(0-?), were significantly different. The results also showed that cocrystal salt could improve drug absorption, blood drug concentration, bioavailability and curative effect. This provides a material basis for reducing dosage and adverse drug reactions. In addition to that the cocrystal salt of this invention can be used as a multi-target drug, it can also combine with other drugs of different action mechanisms to form compound preparations or be used in combination, so as to obtain unexpected clinical efficacy.

Abstract: Optical isomers of phenylpropionic acid drugs are a mixture having R-type optical isomer and S-type optical isomer at a ratio of 10:1-1:10 by weight, wherein the ratio of 1:1 is excluded. A use of the optical isomers includes that the R-type optical isomer is used for manufacturing anti-inflammatory and analgesic drugs and the mixture having the R-type optical isomer and the S-type optical isomer at a ratio of 10:1-1:10 by weight, wherein the ratio of 1:1 is excluded, is used for manufacturing anti-inflammatory and analgesic drugs. The therapeutic indexes of anti-inflammatory and analgesic drugs of the present optical isomers are all higher than those of the S-type optical isomers and the racemate.